Swiss Group for Clinical Cancer Research
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.sakk.ch/
Clinical Trials
139
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (134 trials with phase data)• Click on a phase to view related trials
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
- Conditions
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 156
- Registration Number
- NCT07020065
- Locations
- 🇨🇭
HFR Fribourg, Fribourg, Villars-sur-Glâne, Switzerland
🇨🇭Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- Other: HyperthermiaRadiation: RadiotherapyProcedure: Surgery
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 24
- Registration Number
- NCT06835049
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭EOC - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 50
- Registration Number
- NCT06452394
- Locations
- 🇨🇭
Kantonsspital Graubünden, Chur, GR, Switzerland
🇨🇭Kantonsspital St.Gallen, St. Gallen, SG, Switzerland
🇨🇭Clinique de Genolier, Genolier, VD, Switzerland
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Other: Standard of care
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 162
- Registration Number
- NCT06401980
- Locations
- 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland
🇨🇭Inselspital, Bern, Switzerland
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
- Conditions
- Triple-negative Breast CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- Other: neoadjuvant immuno-chemotherapy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 54
- Registration Number
- NCT06358573
- Locations
- 🇨🇭
Tumor Zentrum Aarau, Aarau, Switzerland
🇨🇭St. Claraspital, Basel, Switzerland
🇨🇭EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, Switzerland
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next